Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Original Article
G.M. Goodwin, S.T. Aaronson, O. Alvarez, P.C. Arden, A. Baker, J.C. Bennett, C. Bird, R.E. Blom, C. Brennan, D. Brusch, L. Burke, K. Campbell-Coker, R. Carhart-Harris, J. Cattell, A. Daniel, C. DeBattista, B.W. Dunlop, K. Eisen, D. Feifel, M. Forbes, H.M. Haumann, D.J. Hellerstein, A.I. Hoppe, M.I. Husain, L.A. Jelen, J. Kamphuis, J. Kawasaki, J.R. Kelly, R.E. Key, R. Kishon, S.K. Peck, G. Knight, M.H. Koolen, M. Lean, R.W. Licht, J.L. Maples-Keller, J. Mars, L. Marwood, M.C. McElhiney, T.L. Miller, A. Mirow, S. Mistry, T. Mletzko-Crowe, L.N. Modlin, R.E. Nielsen, E.M. Nielson, S.R. Offerhaus, V. O’Keane, T. Páleníček, D. Printz, M.C. Rademaker, A.v. Reemst, F. Reinholdt, D. Repantis, J. Rucker, S. Rudow, S. Ruffell, A.J. Rush, R.A. Schoevers, M. Seynaeve, S. Shao, J.C. Soares, M. Somers, S.C. Stansfield, D. Sterling, A. Strockis, J. Tsai, L. Visser, M. Wahba, S. Williams, A.H. Young, P. Ywema, S. Zisook, and E. Malievskaia
N Engl J Med 2022;387:1637-1648
Course summary
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation

Facebook
X
LinkedIn
Forward